NSRX - Earnings announcements

In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"),

TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation. Conference call & webcast info: Monday, March 16, 2026, at 08:00 a.m. ETIndividuals may register for the webcast at